NZ599162A - Compounds having Phosphoinositide 3-kinase Inhibitor Activity - Google Patents

Compounds having Phosphoinositide 3-kinase Inhibitor Activity

Info

Publication number
NZ599162A
NZ599162A NZ599162A NZ59916210A NZ599162A NZ 599162 A NZ599162 A NZ 599162A NZ 599162 A NZ599162 A NZ 599162A NZ 59916210 A NZ59916210 A NZ 59916210A NZ 599162 A NZ599162 A NZ 599162A
Authority
NZ
New Zealand
Prior art keywords
methyl
pyrazolo
pyrimidin
hydroxyphenyl
amino
Prior art date
Application number
NZ599162A
Other languages
English (en)
Inventor
George Hardy
Christopher John Brown
John King-Underwood
Peter John Murray
Frederick Arthur Brookfield
Kazuhiro Ito
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ599162(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of NZ599162A publication Critical patent/NZ599162A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ599162A 2009-10-19 2010-10-19 Compounds having Phosphoinositide 3-kinase Inhibitor Activity NZ599162A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0918249.4A GB0918249D0 (en) 2009-10-19 2009-10-19 Compounds
TW099135360A TWI478923B (zh) 2009-10-19 2010-10-18 喹唑啉酮化合物及其用途
PCT/EP2010/065746 WO2011048111A1 (en) 2009-10-19 2010-10-19 Compounds

Publications (1)

Publication Number Publication Date
NZ599162A true NZ599162A (en) 2013-08-30

Family

ID=41462531

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ599162A NZ599162A (en) 2009-10-19 2010-10-19 Compounds having Phosphoinositide 3-kinase Inhibitor Activity
NZ609147A NZ609147A (en) 2009-10-19 2011-10-18 Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ609147A NZ609147A (en) 2009-10-19 2011-10-18 Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors

Country Status (35)

Country Link
US (4) US8741909B2 (OSRAM)
EP (1) EP2491037B1 (OSRAM)
JP (1) JP5889792B2 (OSRAM)
KR (1) KR101770616B1 (OSRAM)
CN (1) CN102712645B (OSRAM)
AR (1) AR078674A1 (OSRAM)
AU (1) AU2010309832B2 (OSRAM)
BR (1) BR112012009214A2 (OSRAM)
CA (1) CA2777902C (OSRAM)
CL (1) CL2012000981A1 (OSRAM)
CR (1) CR20120264A (OSRAM)
CY (1) CY1116057T1 (OSRAM)
DK (1) DK2491037T3 (OSRAM)
EA (1) EA020330B3 (OSRAM)
EC (1) ECSP12011805A (OSRAM)
ES (1) ES2477270T3 (OSRAM)
GB (1) GB0918249D0 (OSRAM)
HR (1) HRP20140599T1 (OSRAM)
IL (1) IL219248A (OSRAM)
ME (1) ME02064B (OSRAM)
MX (1) MX2012004525A (OSRAM)
MY (1) MY164731A (OSRAM)
NI (2) NI201200061A (OSRAM)
NZ (2) NZ599162A (OSRAM)
PE (1) PE20121390A1 (OSRAM)
PH (1) PH12012500620A1 (OSRAM)
PL (1) PL2491037T3 (OSRAM)
PT (1) PT2491037E (OSRAM)
RS (1) RS53385B (OSRAM)
SI (1) SI2491037T1 (OSRAM)
SM (1) SMT201400086B (OSRAM)
TW (1) TWI478923B (OSRAM)
UA (1) UA108743C2 (OSRAM)
WO (1) WO2011048111A1 (OSRAM)
ZA (1) ZA201203662B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2709257C (en) 2007-12-19 2016-12-13 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
ES2469367T3 (es) 2010-02-01 2014-06-18 Cancer Research Technology Limited 1-(5-Terc-butil-2-fenil-2H-pirazol-3-il)-3-[2-fluoro-4-(1-metil-2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-7-iloxi)-fenil]-urea y compuestos relacionados y su uso en terapia
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
AU2012354094C1 (en) 2011-12-15 2015-10-15 Novartis Ag Use of inhibitors of the activity or function of PI3K
HUE029420T2 (en) * 2012-03-13 2017-02-28 Respivert Ltd Crystalline PI3 kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
JO3279B1 (ar) * 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd “regime de dosagem e formulações para adenovírus de tipo b”
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2019143874A1 (en) * 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN108516976B (zh) * 2018-04-27 2020-07-03 四川大学华西医院 一种7-脱氮嘌呤衍生物及其四元环超分子结构
CN112566639A (zh) * 2018-09-18 2021-03-26 雀巢产品有限公司 用于骨骼肌调节的src抑制剂化合物、其方法和用途
CN114258393B (zh) * 2020-07-21 2024-11-22 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
AU3409399A (en) 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
SI3029041T1 (sl) 2000-04-25 2020-08-31 Icos Corporation Inhibitorji humane delta fosfatidil-inozitol 3-kinaze
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Ｎａｄシンテターゼ阻害剤およびその使用
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US20050002930A1 (en) 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB2453058A (en) * 2006-04-04 2009-03-25 Univ California Kinase antagonists
CN101506211B (zh) * 2006-04-04 2013-05-22 加利福尼亚大学董事会 激酶拮抗剂
JP2009537158A (ja) 2006-05-24 2009-10-29 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 免疫原性の減少を伴った高親和性ヒトおよびヒト化抗−α５β１インテグリン機能阻害抗体
MX2009000107A (es) 2006-06-29 2009-01-23 Schering Corp Antagonistas del receptor de trombina biciclicos y triciclicos sustituidos.
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
EA200901488A1 (ru) * 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
EP2346508B1 (en) * 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
WO2010065923A2 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en) 2008-12-05 2012-10-17 Designmedix Inc CHLOROQUINES MODIFIED BY A MONOCYCLIC GROUP OR A FUSED CYCLE GROUP
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TR201901644T4 (tr) 2010-09-30 2019-02-21 Chiesi Farm Spa İnhalasyon için kuru toz formülasyonlarında magnesyum stearat. kullanımı.
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
HUE029420T2 (en) 2012-03-13 2017-02-28 Respivert Ltd Crystalline PI3 kinase inhibitors

Also Published As

Publication number Publication date
MX2012004525A (es) 2012-05-29
PH12012500620A1 (en) 2015-03-20
HK1173728A1 (en) 2013-05-24
SMT201400086B (it) 2014-09-08
SI2491037T1 (sl) 2014-08-29
BR112012009214A2 (pt) 2016-08-16
PE20121390A1 (es) 2012-10-15
JP5889792B2 (ja) 2016-03-22
CY1116057T1 (el) 2017-02-08
EA201270575A1 (ru) 2012-09-28
US9834560B2 (en) 2017-12-05
NZ609147A (en) 2014-03-28
ECSP12011805A (es) 2012-06-29
HRP20140599T1 (hr) 2014-09-12
MY164731A (en) 2018-01-30
NI201300035A (es) 2013-06-04
AU2010309832B2 (en) 2014-01-30
GB0918249D0 (en) 2009-12-02
EA020330B1 (ru) 2014-10-30
US8741909B2 (en) 2014-06-03
TWI478923B (zh) 2015-04-01
TW201124418A (en) 2011-07-16
EP2491037B1 (en) 2014-04-30
UA108743C2 (uk) 2015-06-10
US20180118754A1 (en) 2018-05-03
US9321773B2 (en) 2016-04-26
AU2010309832A1 (en) 2012-04-19
EP2491037A1 (en) 2012-08-29
JP2013508334A (ja) 2013-03-07
EA020330B3 (ru) 2015-07-30
CA2777902A1 (en) 2011-04-28
CL2012000981A1 (es) 2012-08-31
CR20120264A (es) 2013-01-25
CN102712645B (zh) 2015-10-21
CN102712645A (zh) 2012-10-03
ZA201203662B (en) 2013-10-30
ME02064B (me) 2015-05-20
ES2477270T3 (es) 2014-07-16
KR101770616B1 (ko) 2017-08-23
DK2491037T3 (da) 2014-07-21
IL219248A0 (en) 2012-06-28
WO2011048111A1 (en) 2011-04-28
PT2491037E (pt) 2014-07-11
KR20120114225A (ko) 2012-10-16
NI201200061A (es) 2013-05-15
CA2777902C (en) 2018-03-06
AR078674A1 (es) 2011-11-23
PL2491037T3 (pl) 2014-09-30
US20160264583A1 (en) 2016-09-15
US20140249164A1 (en) 2014-09-04
RS53385B (sr) 2014-10-31
US20120208799A1 (en) 2012-08-16
IL219248A (en) 2015-02-26

Similar Documents

Publication Publication Date Title
NZ599162A (en) Compounds having Phosphoinositide 3-kinase Inhibitor Activity
Abdellatif et al. Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment
US11591342B2 (en) Heterocyclic compound, application thereof and pharmaceutical composition comprising same
AU2016201584B2 (en) Phosphatidylinositol 3-kinase inhibitors
US10596174B2 (en) Pyrrolopyrimidine compounds as inhibitors of protein kinases
ES2314444T3 (es) Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
NZ719972A (en) Pyrazolopyrimidine jak inhibitor compounds and methods
US20240383878A1 (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
US20050222171A1 (en) Organic compounds
NZ590777A (en) PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR INHIBITING mTOR
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
JP2013508334A5 (OSRAM)
NZ702041A (en) Heterocyclic containing entities, compositions and methods
CN1909908A (zh) 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物
WO2008059368A3 (en) Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
ES2664499T9 (es) Pirimidinas sustituidas para el tratamiento de enfermedades tales como el cáncer
CN101535313A (zh) 作为蛋白激酶调节剂的3-氨基羰基取代的稠合的吡唑衍生物
NZ597140A (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
BRPI0613870A2 (pt) derivados da pirazol[1,5-a]pirimidinil-7-il amina como inibidores da proteìna quinase
NZ608718A (en) Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
ES2929406T3 (es) Compuestos de piridonas heterocondensadas y su uso como inhibidores de IDH
ES2917526T3 (es) Compuestos de aminonaptoquinona y composición farmacéutica para bloquear el sistema ubiquitinación-proteasoma en enfermedades
PE20070362A1 (es) COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
MY162461A (en) Substituted benzamide derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 OCT 2017 BY CPA GLOBAL

Effective date: 20140903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 OCT 2018 BY CPA GLOBAL

Effective date: 20170907

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 OCT 2019 BY CPA GLOBAL

Effective date: 20180907

LAPS Patent lapsed